Safety Remains Front-Line Concern For Oral MS Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Two drugs in a race to become the first oral treatment for relapsing forms of multiple sclerosis have high safety hurdles to overcome, obstacles that may knock them both out of the running as first-line treatments.
You may also be interested in...
Biogen Idec Says Tysabri Patient Counts Are On The Upswing
But economy and competitive MS market could provide headwinds going forward.
Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.
Side Effects Dampen Neurologists’ Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change